Revised labeling approved for Cypher stent
A retrospective analysis by the FDA of more than 900 patients has found no increased risk of myocardial infarction with the use of overlapping Cypher stents (sirolimus-eluting coronary stent, Cordis Corp.), leading the agency to approve revised labeling for the product. Overlapping stents are used in patients with complex coronary artery disease when the blockage is too long for a single stent. Approximately 25% of procedures involve overlapping stents. The new labeling can be found at http://www.cypherusa.com/.
Challenges for Pharmacies in 2025: What to Expect and How to Prepare
January 8th 2025Pharmacy professionals are used to overcoming obstacles in this competitive, dynamic field. But the coming year will bring challenges affecting patient care, the industry workforce and their business. Pharmacies must be ready to do more than weather the storm; they need deliberate strategy and sophisticated tools to thrive amidst these obstacles. This white paper will discuss the issues and solutions that should be at the top of every pharmacy professional’s mind as they start the new year.
